Table 2 Conditioning regimens used in SCT1 and SCT2.

From: Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT

 

Myeloablative regimens

Reduced- intensity regimens

 

MAC 1

MAC 2

RIC 1

RIC 2

BuCy

44%

13%

  

FluBua

17%

9%

37%

14%

Melphalan-based

3%

4%

22%

17%

Thiotepa-basedb

0.3%

12%

3%

14%

Treosulfan-based

5%

15%

11%

8%

TBI-basedc

28%

22%

15%

18%

FLAMSA (sequential)d

2%

7%

9%

10%

Others

1%

17%

4%

19%

  1. Abbreviations as in Table 1. MAC 1 myeloablative conditioning in second transplant, MAC 2 myeloablative conditioning in second transplant, RIC 1 reduced intensity conditioning in first transplant, RIC 2 reduced intensity conditioning in second transplant, BuCy high-dose busulfan and cyclophosphamide, TBI total body radiation. aFludarabine and busulfan. Mostly 4 days of busulfan (total 12.8 mg/kg of IV formulation) for MAC and 2 days (6.4 mg/kg) for RIC bMostly the TBF regimen consisting of fludarabine, thiotepa, and busulfan in myeloablative or reduced-intensity doses as previously reported cMostly 12 cGy for MAC and 2–4 cGy for RIC with other agents dSequential therapy of FLAMSA (or other induction regimens) with MAC or RIC subsequent transplant conditioning
Back to article page